Search

Your search keyword '"Voon, Pei Jye"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Voon, Pei Jye" Remove constraint Author: "Voon, Pei Jye" Database Unpaywall Remove constraint Database: Unpaywall
40 results on '"Voon, Pei Jye"'

Search Results

1. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

11. A new era of the Asian clinical research network: a report from the ATLAS international symposium

12. Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia

14. Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

15. International Collaboration on Palliative Care Development Between ASCO and the Land of Hornbills

18. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

19. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial

20. Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

21. Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction

23. A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.

25. Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes

28. Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017

29. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

30. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

32. Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer.

34. Correlation of aldo‐ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients

35. Correlation of pharmacokinetics of CPT-11 in FOLFIRI with phenotyping of CYP3A4 and UGT1A1 activity.

36. Low-dose, short-course sunitinib may normalize tumor vasculature and improve tumor blood flow to enhance chemotherapy efficacy in breast cancers.

Catalog

Books, media, physical & digital resources